|
- Biologicals - World Health Organization (WHO)
Biologicals are a class of medicines made from living cells taken from plants, animals or bacteria These cells are use in creating many types of health care products, including vaccines This group of medicines also includes products derived from human blood and plasma for the treatment of many life-threatening diseases and for surgical procedures
- Call for applications closed - 2025 Introductory course for biologics . . .
Call for applications closed - 2025 Introductory course for biologics development and manufacturing organised by the Global Training Hub for Biomanufacturing (GTH-B) in Seoul, Republic of Korea Deadline for applications: 07 March 2025 18:00 (KST)
- Guidelines for Biologicals
Guidelines for the production and control of inactivated oral cholera vaccine, Annex 3, TRS No 924 Guidelines for the production and control of inactivated oral cholera
- WHO good manufacturing practices for biological products
Good manufacturing practices (GMP) for biological products were first published by WHO in 1992 (1) This current revision reflects subsequent developments that have taken place in science and technology, and in the application of risk-based approaches to GMP (2–14) The content of this document should be considered complementary to the general recommendations set out in the current WHO good
- mRNA Technology Transfer (mRNA TT) Programme
The mRNA Technology Transfer (mRNA TT) Programme aims to build sustainable regional production of mRNA-based health products, preparing for future pandemics and ensuring sustainability in-between global health emergencies
- WHO adds LC16m8 mpox vaccine to Emergency Use Listing
This is the largest donation package announced to date in response to the current mpox emergency LC16m8 is a vaccine developed and manufactured by KM Biologics in Japan The Technical Advisory Group (TAG) for EUL of vaccines convened to discuss the outcome of the LC16m8 vaccine review, including the product and programmatic suitability
- Biologics Development and Manufacturing -introductory course available . . .
Low- and Middle-Income Countries (LMICs) face significant inequity in terms of access to vaccines and other biologics and are making efforts to establish biological manufacturing in their regions Establishing such manufacturing capacity, through bilateral technology transfer or through local R D efforts is frequently hampered by the lack of a workforce trained in biomanufacturing To address
- Introductory Course for Biologics Development and Manufacturing . . .
Low- and Middle-Income Countries (LMICs) face significant inequity in terms of access to vaccines and other biologics and are making efforts to establish biological manufacturing in their regions Establishing such manufacturing capacity, through bilateral technology transfer or through local R D efforts is often hindered by the lack of a trained workforce in biomanufacturing To address this
|
|
|